Genome-based pharmacogenetics and the pharmaceutical industry

Nature Reviews Drug Discovery

Volumn 1, Issue 7, 2002, Pages 541-549

  Roses, Allen D ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; GLUCURONOSYLTRANSFERASE; HLA B ANTIGEN; TRANILAST; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; PROTEOME;

CLINICAL TRIAL; DIAGNOSTIC VALUE; DRUG INDUSTRY; DRUG SURVEILLANCE PROGRAM; FEVER; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MAPPING; GENE MUTATION; GENE SEQUENCE; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HLA TYPING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERSENSITIVITY REACTION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALAISE; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEOMICS; RASH; RESPIRATORY TRACT DISEASE; RESTENOSIS; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSLUMINAL CORONARY ANGIOPLASTY; GENOME;

CLINICAL TRIALS; DIDEOXYNUCLEOSIDES; DRUG INDUSTRY; GENETIC PREDISPOSITION TO DISEASE; GENOME; HUMANS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEOME;

EID: 0036633359     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd840     Document Type: Review

References (52)

1. Motulsky, A. J. Pharmacogenetics and ecogenetics in 1991. Pharmacogenetics 1, 2-3 (1991).
2. Pfsot, D. R., Boyce-Jacino, M. T., & Grant, D. M. A SNPshot: pharmacogenetics and the future of drug therapy. Trends Biotechnol 18, 334-338 (2000).
3. Edwards, R. & Aronson, J. K. Adverse drug reactions: definitions, diagnosis, and management. Lancet 356, 1255-1259 (2000).
4. McLeod, H. L. & Evans, W. E. Pharmacogenomics: unlocking the human genome for better drug therapy, Annu. Rev. Pharmacol. Toxicol. 41, 101-121 (2000).
5. Sadee, W. Pharmacogenomics: using genetic information to optimize drug therapy. Medscape Pharmacotherapy [onine] (cited 10 Jun. 02) (2000).
6. Kurth, J. H. Pharmacogenomics: future promise of a tool for identifying patients at risk. Drug Info. J. 34, 223-227 (2000).
7. Roses, A. D. Pharmacogenetics and the practice of medicine. Nature 405, 857-865 (2000).
8. Roses, A. D. Pharmacogenetics. Hum. Mol. Genet. 10, 2261-2267 (2001).
9. Evans, W. E. & Johnson, J. A. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu. Rev. Genomics Hum. Genet 2. 9-39 (2001).
10. Pimohamed, M. & Park, B. K. Genetic susceptibility to adverse drug reactions. Trends Pharmacol. Sci. 22, 298-305 (2001).
11. Fiijal, B. A., Hall, J. M. & Witte, J. S. Clinical trials in the genomic era: effects of protective genotypes on sample size and duration of trial. Control. Clin. Trials 21, 7-20 (2000).
12. Lazarou, J., Pomeranz, B. H., & Corey, P. N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279, 1200-1205 (1998).
13. Jeffries, D. B., Leakey D., Lewis, J. A., Payne, S. & Rawlins, M. D. New active substances authorized in the United Kingdom between 1972 and 1994. Br. J. Clin. Pharmacol. 45, 151-156 (1998).
14. Pirmohamed, M., Breckenridge, A. M., Kitteringham, N. R., & Park, B. K. Adverse drug reactions. BMJ 316, 1295-1298 (1998).
15. Wieczorek, S. J. & Tsongalis, G. J. Pharmacogenomics: will it change the field of medicine? Clin. Chim. Acta 308, 1-8 (2001).
16. Lesko, L. J. & Woodcock, J. Pharmacogenomic-guided drug development: regulatory perspective. Pharmacogenomics J. 2, 101-103 (2002).
17. The SNP Consortium. (2002).
18. Roses, A. D. Pharmacogenetics place in modern medical science and practice. Life Sci, 70, 1471-1480 (2002).
19. Lai, E., Riley, J., Purvis, I. & Roses, A. D. A 4-Mb high-density single nucleotide polymorphism-based map around human APOE. Genomics 54, 31-38 (1998)
20. Roses, A. D. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu. Rev. Med 47, 387-400 (1996).
21. Farrer, L. A. et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278, 1349-1356 (1997).
22. Tang, M. X. et al. The APOE E4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. J. Am. Med. Assoc. 279, 751-755 (1998).
23. Graff-Radford, N. R. et al. Association between apolipoprotein E genotype and Alzheimer disease in African American subjects. Arch. Neurol. 59, 594-600 (2000).
24. Kardaun, J. W. et al. Genotypes and phenotypes for apolipoprotein E and Alzheimer disease in the Honolulu-Asia aging study. Clin. Chem. 46, 1548-1554 (2000).
25. Martin, E. R. et al. SNPing away at complex diseases: analysis of single-nucleotide polymorphisms around APOE in Alzheimer disease. Am. J. Hum. Genet. 67, 383-394 (2000).
26. Martin, E. R. et al. Analysis of association at SNPs in the APOE region. Genomics 63, 7-12 (2000).
27. McCarthy, L. C. et al. Single-nucleotide polymorphism alleles in the insulin receptor gene are associated with typical migraine. Genomics 78, 135-149 (2001).
28. Hewett, D. et al. Identification of a psoriasis susceptibility candidate gene by linkage disequilibrium mapping with a localized single nucleotide polymorphism map. Genomics 79, 305-314 (2002).
29. Rioux, J. D. et al. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nature Genet. 29, 223-228 (2001).
30. Bergstresser, P. R. Sensitization and elicitation of inflammation in contact dermatitis. Immunol. Ser. 46, 219-245 (1989).
31. Fleming, C. J., Burden, A. D. & Forsyth, A. The genetics of allergic contact hypersensitivity to nickel. Contact Dermatitis 41, 251-253 (1999).
32. Ardlie, K. G., Kruglyak, L. & Seielstad, M. Patterns of linkage disequilibrium in the human genome. Nature Rev. Genet. 3, 299-309 (2002).
33. Cantor, C. Whole genome SNP scans: the reality. The Human Genome Organisation [online] (cited 31 May 2002) (2002).
34. Foster, R. H. & Foulds, D. Abacavir. Drugs 55, 729-736 (1998).
35. Symonds, W. et al, Risk factor analysis for hypersensitivity reactions to abacavir. Clin. Ther. (in the press).
36. Hetherington, S. W. et al. Hypersensitivity reactions during therapy with abacavir: analysis of 636 cases for clinical presentation and risk factors. [online] (cited 31 May 2002) 7th Conference on Retroviruses and Opportunistic Infections (2000).
37. Brew, B. J. et al. Phase III, randomized, double-blind, placebo controlled, multicentre study to evaluate the safety and efficacy of abacavir (ABC 1592) in HIV-1 infected subjects with AIDS dementia complex (CNA3001). 12th World AIDS Conference Abstract 32,192 (1998).
38. Brinkman, K., Smeitink, J. A., Romijn, A., & Reiss, P. Mitochondrial toxicity induced by nucleoside-analogue reverse transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 354, 1112-1115 (1999).
39. Hetherington, S. et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359, 1121-1122 (2002).
40. Mallal, S. et al. Association between the presence of HLA-B*5701, HLA-DR7, and HLA-GQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359, 727-732 (2002).
41. Monaghan, G., Ryan, M., Seddon, H. R. & Burchell, B. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 347, 578-581 (1996).
42. Aono, S. et al. Analysis of genes for bilirubin UPD-glucuronosyltransferase in Gilbert's syndrome. Lancet 345, 958-959 (1995).
43. Bosma, P. J. et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N. Engl. J. Med. 333, 1171-1175 (1995).
44. Bosma, P. J. et al. Sequence of exons and the flanking region of human bilirubin-UDP-glucuronosyltransferase gene complex and identification of a genetic mutation in a patient with Crigler-Najjar syndrome, type I. Hepatology 15, 941-947 (1992).
45. Roses, A. D. Pharmacogenetics and future drug development and delivery. Lancet 355, 1358-1361 (2000).
46. Petricoin, E. F. et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359, 572-577 (2002).
47. Buchanan, A. et al. Pharmacogenetics: ethical issues and policy options. Kennedy Inst. Ethics J. (in the press).
48. Robertson, J. A. Pharmacogenetic challenges for the health care system. Health Affairs (in the press).
49. Wolf, C. R., Smith, G. & Smith, R. L. Science, medicine and the future: pharmacogenetics. BMJ 320, 987-990 (2000).
50. Ingelman-Sundberg, M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J. Int. Med. 250, 186-200 (2001).
51. Park, K. B. & Pirmohamed, M. Toxicogenetics in drug development. Toxicol. Lett. 120, 281-291 (2001).
52. Cardon, L. R. et al. Testing drug response in the presence of genetic information: sampling issues for clinical trials. Pharmacogenetics 10, 503-510 (2000).